Earnings
AVTX
2.390
-5.91%
-0.150
Currencies: USD
Items
Net Income
Depreciation and Amortization
Deferred Tax
Unamortized Expenditures
Accrued Expenses
Share-based Compensation
Assets Disposal
Financial Expenses
Investment Loss
Working Capital Change
Other Items
Operating Activities
Purchases of Fixed Assets
Proceeds from Disposal of Fixed Assets
Investment Expenditure
Investment Income
Other Investing Activities
Investing Activities
Issuance of Capital Stock
Issuance of Bonds
Proceeds from Borrowings
Dividend Payments
Repayment of Borrowings
Buyback Payments
Stock Incentive Compensation
Other Financing Activities
Financing Activities
Effect of Exchange Rate Changes 
Net Increase in Cash,Cash Equivalents
FY 2020-12-31
-63.50M
1.84M
195.59K
--
--
--
25.36M
--
--
-4.44M
--
-40.54M
-62.66K
--
--
--
11.19M
11.13M
40.99M
0.00
--
--
--
--
--
--
44.78M
--
15.38M
FY 2019-12-31
-16.07M
3.88M
16.74K
--
--
--
-4.94M
--
--
-2.03M
--
-19.13M
-262.01K
--
--
--
-180.99K
-443.00K
10.02M
-256.14K
--
--
--
--
--
--
12.56M
--
-7.02M
FY 2018-12-31
-40.05M
4.55M
-16.75K
--
--
--
23.65M
--
--
8.73M
--
-3.13M
-564.42K
--
--
--
1.43M
865.46K
6.84M
0.00
--
--
--
--
--
--
10.40M
--
8.14M
FY 2017-12-31
11.87M
425.48K
-832.63K
--
--
--
1.35M
--
--
-229.03K
--
12.58M
-23.33K
--
--
--
-18.89M
-18.91M
1.74M
-2.37M
--
--
--
--
--
--
3.74M
--
-2.60M
FY 2016-12-31
-16.47M
26.86K
--
--
--
--
1.78M
--
--
87.07K
--
-14.57M
-34.88K
--
--
--
--
-34.88K
2.00M
-3.31M
--
--
--
--
--
--
-1.43M
--
-16.03M

FY: Financial Year. It represents annual report.

Q: Quarter Report. Q1、Q2、Q3、Q4 represent three-month periodic financial reports.

Check out AVTX latest annual and quarterly financial reports. There are also historical financial reports for you to reference. You can analyze Avalo Therapeutics Inc recent business situations by check its cash flow statements, balance sheets, income statements and other tables. Comprehensive data may help you to understand and analyze AVTX development prospects in various aspects, and this information may help you to better grasp the Avalo Therapeutics Inc operation.